Cargando…

HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers

Triple negative breast cancers (TNBCs) represent 15–20% of all breast cancers and are associated with higher recurrence and distant metastasis rate. Standard of care for early stage TNBC is anthracyclines combined with cyclophosphamide (AC) followed by taxanes, in the neo‐adjuvant or adjuvant settin...

Descripción completa

Detalles Bibliográficos
Autores principales:	El‐Botty, Rania, Vacher, Sophie, Mainguené, Juliette, Briaux, Adrien, Ibadioune, Sabrina, Dahmani, Ahmed, Montaudon, Elodie, Nemati, Fariba, Huguet, Léa, Sourd, Laura, Morriset, Ludivine, Château‐Joubert, Sophie, Dubois, Thierry, Maire, Virginie, Lidereau, Rosette, Rapinat, Audrey, Gentien, David, Coussy, Florence, Bièche, Ivan, Marangoni, Elisabetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552896/ https://www.ncbi.nlm.nih.gov/pubmed/36852691 http://dx.doi.org/10.1002/1878-0261.13412

Ejemplares similares

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
por: Coussy, F., et al.
Publicado: (2020)

HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast
por: Bièche, Ivan, et al.
Publicado: (2021)

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
por: Coussy, Florence, et al.
Publicado: (2020)

Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant
por: Jacquemetton, Julien, et al.
Publicado: (2021)

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers
por: ter Brugge, Petra, et al.
Publicado: (2023)

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance
por: Montaudon, Elodie, et al.
Publicado: (2020)

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition
por: El Botty, Rania, et al.
Publicado: (2018)

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers
por: Hatem, Rana, et al.
Publicado: (2016)

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
por: El-Botty, Rania, et al.
Publicado: (2023)

MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?
por: Cizeron-Clairac, Geraldine, et al.
Publicado: (2015)

NF-kappa B genes have a major role in Inflammatory Breast Cancer
por: Lerebours, Florence, et al.
Publicado: (2008)

High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC
por: Montaudon, Elodie, et al.
Publicado: (2021)

Gene Expression Profiling Reveals New Aspects of PIK3CA Mutation in ERalpha-Positive Breast Cancer: Major Implication of the Wnt Signaling Pathway
por: Cizkova, Magdalena, et al.
Publicado: (2010)

Distinct expression profiles and functions of Kindlins in breast cancer
por: Azorin, Paula, et al.
Publicado: (2018)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels
por: Rondeau, S, et al.
Publicado: (2015)

PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups
por: Cizkova, Magdalena, et al.
Publicado: (2012)

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer
por: Spasojevic, Caroline, et al.
Publicado: (2018)

Update on inflammatory breast cancer
por: Lerebours, Florence, et al.
Publicado: (2005)

The high protein expression of FOXO3, but not that of FOXO1, is associated with markers of good prognosis
por: Lallemand, François, et al.
Publicado: (2020)

PIK3R1 underexpression is an independent prognostic marker in breast cancer
por: Cizkova, Magdalena, et al.
Publicado: (2013)

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings
por: Bieche, Ivan, et al.
Publicado: (2014)

A Molecular Predictor Reassesses Classification of Human Grade II/III Gliomas
por: Rème, Thierry, et al.
Publicado: (2013)

Similar NF-κB Gene Signatures in TNF-α Treated Human Endothelial Cells and Breast Tumor Biopsies
por: Perrot-Applanat, Martine, et al.
Publicado: (2011)

Identification of a three-gene expression signature of poor-prognosis breast carcinoma
por: Bièche, Ivan, et al.
Publicado: (2004)

Clinical value of R-spondins in triple-negative and metaplastic breast cancers
por: Coussy, F, et al.
Publicado: (2017)

Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma
por: Bièche, Ivan, et al.
Publicado: (2004)

Spontaneous mouse lymphoma in patient-derived tumor xenografts: The importance of systematic analysis of xenografted human tumor tissues in preclinical efficacy trials
por: Chateau-Joubert, Sophie, et al.
Publicado: (2021)

WWOX binds MERIT40 and modulates its function in homologous recombination, implications in breast cancer
por: Taouis, Karim, et al.
Publicado: (2023)

Involvement of the FOXO6 transcriptional factor in breast carcinogenesis
por: Lallemand, François, et al.
Publicado: (2017)

Mouse HORMAD1 and HORMAD2, Two Conserved Meiotic Chromosomal Proteins, Are Depleted from Synapsed Chromosome Axes with the Help of TRIP13 AAA-ATPase
por: Wojtasz, Lukasz, et al.
Publicado: (2009)

Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy
por: Bièche, Ivan, et al.
Publicado: (2011)

Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer
por: Meseure, Didier, et al.
Publicado: (2016)

Kindlin‐1 modulates the EGFR pathway and predicts sensitivity to EGFR inhibitors across cancer types
por: Azorin, Paula, et al.
Publicado: (2022)

HORMAD2 methylation‐mediated epigenetic regulation of gene expression in thyroid cancer
por: Lin, Qiuyu, et al.
Publicado: (2018)

Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft
por: Passeri, Thibault, et al.
Publicado: (2022)

Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity
por: Wang, Xian, et al.
Publicado: (2018)

Hormad1 Mutation Disrupts Synaptonemal Complex Formation, Recombination, and Chromosome Segregation in Mammalian Meiosis
por: Shin, Yong-Hyun, et al.
Publicado: (2010)

Hedgehog pathway activation in human transitional cell carcinoma of the bladder
por: Pignot, G, et al.
Publicado: (2012)

Correction: Hormad1 Mutation Disrupts Synaptonemal Complex Formation, Recombination, and Chromosome Segregation in Mammalian Meiosis
por: Shin, Yong-Hyun, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3b5rh88kgb6lptauaaistbd0uj